TO THE EDITOR: Scott and colleagues' findings (1) are not particularly surprising. Employment by hospital systems alone does not necessarily affect the quality of care provided. Belief that it does is partly based on the authors' false assumption that hospital-employed physicians "are less likely to focus on generating revenue to maintain an independent practice and more likely to focus on patient care." This statement seems to assume that these employment arrangements are based on salary rather than productivity. In general, physician employment agreements with hospitals remain largely productivitybased (dependent on, for example, encounters and work relative value units). On the basis of our group's participation in a national survey of large affiliated groups, approximately 90% of physician compensation remains productivity-based, whereas 10% is value-based (dependent on, for example, patient satisfaction, citizenship, and quality metrics).
To date, the primary driver for hospital systems to employ physicians is to ensure that these systems have a more stable revenue stream. Most physicians coming out of training are not looking for positions in private practice, with all of its administrative hassles; therefore, physicians who have embraced private practice cannot easily recruit or retain physicians. At the same time, many physicians in private practice are finding the business and regulatory burdens untenable and are looking for hospital system-affiliated employment opportunities. As such, for hospital systems, physician employment seems primarily a matter of financial survival. Although the pursuit of quality is noble, it is not the primary driver of the affiliation changes that Scott and colleagues describe.
In my experience, the pursuit of improved quality of care is not magic. It does not arise spontaneously out of an employment agreement. What is required is time and attention, usually from a team of persons who can understand processes and workflows, perform gap analyses, and use various tools inherent to process improvement. In general, if you want physicians to participate in this process, you need to offset reduction in income based on lower productivity with a stipend that covers their lost opportunity. As Scott and colleagues note, "by employing physicians, hospitals can more closely direct their activities and drive changes in care." With largely productivity-based employment agreements, for that to happen hospital systems must be willing to separately reimburse physicians for those activities. TO THE EDITOR: I read Scott and colleagues' article (1) with interest. Between October 2008 and August 2016, I functioned in a position akin to chief medical information officer at a midsized rural hospital. We rapidly acquired practices during that period, largely because of the increasing administrative burden of private practice and the economics of rural practice in central Maine. I had substantial responsibility for integrating practices into our EHR and enhancing its function.
We used our EHR as a means of driving and standardizing care among our current employees. Thus, I was in a position to observe the evolution of behavior as our private practice physicians became employees.
A minimum of 4 to 6 months was generally required for a practice and its physicians to become acclimated to our EHR. We usually implemented the EHR in stages (retrieval of data, orders/prescriptions, and documentation) to minimize the effect on productivity and reduce the stress of the transition. At that point, we would start holding practices and persons accountable for adhering to the standards and expectations set previously and enforced for our employed physicians. This, too, was introduced gradually, and a newly employed physician could be considered fully integrated into our system only after a year of employment. This timeline applied to other aspects of performance and integration, not just function within the EHR.
The process of ending one's private practice is painful. I went through it before moving to the world of medical information technology. There is a sense of failure in needing to give up something that you have built. There is a natural resistance to being told what to do after setting your own rules for the past 20-odd years. There is a chafing under what might seem to be mindless bureaucracy (sometimes it is, but often it is the difference between running a small office and a big medical center). There is the shock and disruption of simply needing to do things differently after doing them your own way. Physicians changing status from private to employed are not the same as "new hires." They are older and set in their ways, and the transition is not always comfortable. These are folks not working at their peak efficiency or job satisfaction. Finally, implementation of a protocol or standardization of a process is sometimes time-consuming, disruptive, and initially met with resistance.
I thus believe that 2 years is too short a time to judge success or failure. My gut tells me that the benefits for quality of care of having hospital-employed physicians outweigh the negatives. There is more accountability, more expert knowledge available in a large organization, and more resources with which to make things happen. Scott and colleagues are to be commended for trying to assess effect in an objective fashion. However, doing so in 2 years may be a rush to judgment. 
Edward Ringel, MD

IN RESPONSE:
We agree with Dr. Bedsole that, as others have found, financial motivations often underlie the real reasons that hospitals acquire physician practices (1). We also agree that there are substantial and growing challenges to the private practice of medicine and that whether this form of practice will be sustainable in the long run is uncertain.
Dr. Ertle notes the important nuance that an employment model does not mean that physicians are not compensated based on financial productivity. Our point in the statement that he quotes is that hospitals can use these arrangements to drive quality, but the evidence suggests that they are not, on average, doing so. However, we appreciate that the term employment and how these arrangements are operationalized may vary greatly across different hospital settings, thereby making it challenging to capture the precise effect of these arrangements on quality.
We are grateful for Dr. Ringel's comments about the difficulty of making this transition work and the timeline examined in our study. His personal account of guiding the transition of previous private physicians to a hospital-employment model provides valuable insight into the dramatic changes that are under way to promote such acquisitions and that such changes do, indeed, take time. Although we agree that it may take many years, our findings suggest that there have been no meaningful gains in quality at least 2 full years after the transition. Whether a longer posttransition period will yield better results is unclear but does suggest that policymakers should not look to hospital acquisition of physician practices as a quick fix that will lead to better care within a few years. First, the authors found that 10.9% of U.S. injection drug users had positive results for HHpgV-1 RNA. This prevalence is much higher than in the United Kingdom (1.7%) (2) and even higher than what we found in China (5.7%), indicating the importance of determining high-risk populations or subpopulations as well as regions in which HHpgV-1 infection is epidemic.
Second, it is believed that HHpgV-1 is a bloodborne virus transmitted through percutaneous blood exposure (2-4). However, we and others have observed that it is rarely detected in persons with either HIV-1 or hepatitis B virus infection (2) (3) (4) (5) . Even in persons with HCV infection, which seems to be strongly associated with HHpgV-1, prevalence has been reported to be only 1.3% to 1.5% in the United States (3, 4) and 1.2% in China (5). In contrast, we and the authors found that persons co-infected with HCV and HIV-1 are much more susceptible to HHpgV-1 infection (1, 5) . This finding indicates the importance of co-infection with these viruses to HHpgV-1 infection, although the role of HIV-1 remains unclear.
Finally, Kandathil and colleagues suggest that the higher prevalence of HHpgV-1 infection in injection drug users is due to high-risk injection practices or frequent blood exposure. However, the current literature involving patients with either HCV or HIV-1 infection indicates that frequent blood exposure alone may not be sufficient to explain the strong association between HHpgV-1 and HCV infection and the high prevalence of HHpgV-1 infection in HCV and HIV-1 co-infected persons (2) (3) (4) (5) . Therefore, we suggest that the association among HCV, HIV-1, and HHpgV-1 infection implies an interaction among these viruses. We believe that HCV may be required for the replication of HHpgV-1 and further hypothesize that HIV-1 increases the replication and viral load of HCV, which in turn supports the replication of and persistent infection with HHpgV-1 by a mechanism that remains to be elucidated. Further studies will clearly be critical for a deeper understanding of the phenomena reported in Kandathil No HPgV-2 RNA was detected in the 1597 samples investigated, regardless of the method used or the donors' geographic origin or HCV infection status. These results concurred with those from a study reporting no HPgV-2 sequences in pools of U.S. and European plasma samples (4) . Sample quality, the presence of inhibitors, or both were eliminated by successfully quantifying the HCV RNA viral load (range, 4 to 7 log 10 IU/mL). The high-throughput sequencing procedure was validated by identifying HHpgV-1 (formerly GB virus C) RNA sequences in approximately 11% of the African samples investigated. The HPgV-2 RNA viral loads reported so far (range, 2.5 to 6.6 log 10 copies/mL) exceed the detection limit of the real-time, quantitative reverse transcriptase polymerase chain reaction assay used (100 RNA copies per reaction using an in vitro, synthesized, NS2-3 sequence [GenBank accession number KT439329]), decreasing the risk for false-negative results related to a lack of sensitivity (5). Genetic diversity of HPgV-2 strains from donors of different geographic origins may negatively affect RNA detection, because approximately 5% nucleotide diversity was observed between the North American HPgV-2 sequences available. Nucleotide substitutions in the reverse primer or probe annealing sites or both did not affect detection (3) .
The absence of detectable HPgV-2 RNA in HCV-infected blood donors from France and China may be related to a lower prevalence of this virus than that reported in the U.S. donors, possibly associated with the difference in exposure. In our study, risk factors were documented for 636 of 860 (74%) HCV-infected French donors, with 114 (18%) reporting previous injection drug use. The difference between studies might be related to Kandathil and colleagues' specific selection of apparently active injection drug users with evidence of multiple bloodborne virus infections (1) . Exposure of HPgV-2 in blood donors may be underestimated because of the inability to serologically detect potential recovered infections in our and Kandathil and colleagues' studies because validated immunoassays are unavailable. Further investigations using larger cohorts and standardized, sensitive assays are required to determine the global epidemiology and natural history of this new virus to estimate its potential pathogenicity, but its effect on blood safety currently seems limited. 
Daniel Candotti, PhD
